Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
roniciclib (BAY1000394)
i
Other names:
BAY1000394, BAY 1000394
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Bayer
Drug class:
CDK inhibitor
Related drugs:
‹
SNS-032 (4)
MK-7965 (4)
PHA 793887 (1)
AT7519 (0)
R-547 (0)
RGB-286638 (0)
E7070 (0)
P27600 (0)
SNS-032 (4)
MK-7965 (4)
PHA 793887 (1)
AT7519 (0)
R-547 (0)
RGB-286638 (0)
E7070 (0)
P27600 (0)
›
Associations
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies (NCT01188252)
Phase 1
Bayer
Bayer
Completed
Phase 1
Bayer
Completed
Last update posted :
01/09/2017
Initiation :
08/01/2010
Primary completion :
06/01/2016
Completion :
12/01/2016
CASP3 • CDKN1A • ANXA5
|
MCL1 expression
|
roniciclib (BAY1000394)
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors (NCT02656849)
Phase 2
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Withdrawn
Phase 2
Dana-Farber Cancer Institute
Withdrawn
Last update posted :
07/01/2016
Initiation :
02/01/2016
Primary completion :
10/01/2019
Completion :
05/01/2023
MYC • CCNE1 • MCL1
|
MYC amplification • CCNE1 amplification • MCL1 amplification
|
roniciclib (BAY1000394)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login